MARKET

PULM

PULM

Pulmatrix
NASDAQ
3.550
-0.100
-2.74%
Closed 16:00 11/28 EST
OPEN
3.580
PREV CLOSE
3.650
HIGH
3.620
LOW
3.530
VOLUME
8.63K
TURNOVER
14.81K
52 WEEK HIGH
15.60
52 WEEK LOW
3.165
MARKET CAP
12.92M
P/E (TTM)
-0.5190
1D
5D
1M
3M
1Y
5Y
Pulmatrix Q3 EPS $(1.45) Up From $(1.80) YoY, Sales $1.87M Up From $1.07M YoY
Benzinga · 11/10 14:30
Pulmatrix GAAP EPS of -$1.45 beats by $0.06, revenue of $1.87M beats by $0.71M
Seekingalpha · 11/10 14:12
-- Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.9M
-- Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.9M
MT Newswires · 11/10 09:15
Pulmatrix Completes Patient Dosing for Phase 1 Study of Acute Migraine Drug Candidate
Pulmatrix Completes Patient Dosing for Phase 1 Study of Acute Migraine Drug Candidate
MT Newswires · 09/26 11:44
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million.
Benzinga · 09/22 12:19
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Pulmatrix (NASDAQ:PULM) shares rose 11.9% to $4.3 during Wednesday's after-market session. The company's market cap stands at $14.5 million.
Benzinga · 09/21 21:36
Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket
Gainers ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading.
Benzinga · 08/25 12:12
Pulmatrix GAAP EPS of -$1.36 beats by $0.15, revenue of $1.33M beats by $0.17M
Pulmatrix press release (<span class="ticker-hover...
Seekingalpha · 08/08 13:15
More
About PULM
Pulmatrix, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs. It designs and develops inhaled therapeutic products based on its dry powder delivery technology, inhaled small particles easily respirable and emitted (iSPERSE), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE’s lead development program, Pulmazole is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. PUR1800 is developing for the treatment of acute exacerbations of chronic obstructive pulmonary disease and PUR3100 is developing for the treatment of acute migraine.

Webull offers kinds of Pulmatrix Inc stock information, including NASDAQ:PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PULM stock methods without spending real money on the virtual paper trading platform.